Oncologist Questions Whether Labeling DCIS as Cancer Drives Over-Treatment
Ductal carcinoma in situ (DCIS), often labeled stage 0 breast cancer, involves abnormal cells confined to breast ducts without spreading. While traditionally treated with surgery, radiation, or hormonal therapy, experts are increasingly questioning whether the 'cancer' label leads to unnecessary interventions. Recent studies suggest DCIS does not always progress to invasive cancer, prompting a shift toward personalized treatment decisions based on individual risk tolerance rather than automatic aggressive therapy. Mammograms remain the primary detection tool, though screening recommendations currently target ages 40 to 74.
